¹⁸F-FDG-PET/CT-guided radiotherapy of cervical lymph nodes in head and neck squamous cell carcinoma

Abstract

The use of positron emission tomography with fluor-18-fluorodeoxyglucose (FDG-PET) in clinical practice for patients with head and neck squamous cell carcinoma (HNSCC) has expanded rapidly, with implications for diagnostic staging, radiotherapy planning, adaptive radiotherapy, and post-therapy evaluation. The implementation of FDG-PET/CT in radiation treatment planning not only has consequences for target volume definition and dose prescription but is also associated with an increased overall survival in patients with HNSCC. FDG-PET/CT-guided gradient dose prescription provides a window of opportunity for treatment de-intensification of the neck in order to decrease treatment-related toxicity without compromising oncological outcome. Further, interim FDG-PET/CT during radiotherapy can be useful to assess metabolic tumor response and enables opportunities for adaptive treatment strategies. The goals are to increase treatment effectivity in poor responders and reduce unnecessary toxicity in patients with good early tumor response. Further prospective trials investigating adaptive radiotherapy based on interim PET-evaluation are needed, especially regarding human papilloma virus-negative HNSCC and patients treated with primary radiotherapy.

Keywords

Head and neck cancer / radiotherapy / FDG-PET / imaging / nodal metastases

References

[1] Brizel DM,Fisher SR.Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.N Engl J Med1998;338:1798-804

[2] Pignon JP,Maillard E.Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.Radiother Oncol2009;92:4-14

[3] Forastiere AA,Maor M.Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.N Engl J Med2003;349:2091-8

[4] Maccomb WS.Planned combination of surgery and radiation in treatment of advanced primary head and neck cancers.Am J Roentgenol Radium Ther Nucl Med1957;77:397-414

[5] den Brekel MW. Lymph node metastases: CT and MRI.Eur J Radiol2000;33:230-8

[6] de Bondt RB,Bakers F.Morphological MRI criteria improve the detection of lymph node metastases in head and neck squamous cell carcinoma: multivariate logistic regression analysis of MRI features of cervical lymph nodes.Eur Radiol2009;19:626-33 PMCID:PMC2816250

[7] Takes RP,Manni JJ.Regional metastasis in head and neck squamous cell carcinoma: revised value of US with US-guided FNAB.Radiology1996;198:819-23

[8] de Bondt RB,Hofman PA.Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging.Eur J Radiol2007;64:266-72

[9] Zhou SM,Marks LB.Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation.Med Phys2004;31:2577-83

[10] Kim SJ,Kim K.Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients; A systematic review and meta-analysis.Am J Otolaryngol2019;40:297-305

[11] Sun R,Yang Y.(18)FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis.Oral Oncol2015;51:314-20

[12] Yongkui L,Wanghan .18FDG-PET/CT for the detection of regional nodal metastasis in patients with primary head and neck cancer before treatment: a meta-analysis.Surg Oncol2013;22:e11-6

[13] Lowe VJ,Subramaniam RM.Multicenter trial of [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography staging of head and neck cancer and negative predictive value and surgical impact in the N0 neck: results from ACRIN 6685.J Clin Oncol2019;37:1704-12 PMCID:PMC6638599

[14] Roh JL,Kim JS.18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.Radiology2014;271:153-61

[15] Yamazaki Y,Notani K.Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer.Ann Nucl Med2008;22:177-84

[16] Yoon DY,Chang SK.CT, MR, US,18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck.Eur Radiol2009;19:634-42

[17] Ong SC,Lee NY.Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.J Nucl Med2008;49:532-40

[18] Schöder H,Lee N.PET monitoring of therapy response in head and neck squamous cell carcinoma.J Nucl Med2009;50 Suppl 1:74S-88S

[19] Helsen N,Carp L.FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance.Eur J Nucl Med Mol Imaging2018;45:1063-71

[20] Van den Wyngaert T,Carp L.Fluorodeoxyglucose-positron emission tomography/computed tomography after concurrent chemoradiotherapy in locally advanced head-and-neck squamous cell cancer: The ECLYPS Study.J Clin Oncol2017;35:3458-64

[21] Bussink J,Kaanders JH.PET-CT for response assessment and treatment adaptation in head and neck cancer.Lancet Oncol2010;11:661-9

[22] Mehanna H,McConkey CC.PET-CT surveillance versus neck dissection in advanced head and neck cancer.N Engl J Med2016;374:1444-54

[23] Dornfeld K,Simmons J.Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy.Int J Radiat Oncol Biol Phys2008;71:386-92 PMCID:PMC2699674

[24] Delouya G,Houle A.¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.Radiother Oncol2011;101:362-8

[25] Guido A,Rombi B.Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer.Int J Radiat Oncol Biol Phys2009;73:759-63

[26] Koshy M,Howell R,Halkar R.F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer.Head Neck2005;27:494-502

[27] Mazzola R,Ricchetti F.18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes.Radiol Med2017;122:952-9

[28] van den Bosch S,Dijkema T.¹⁸F-FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival.Radiother Oncol2020;142:107-14

[29] van den Bosch S,Raaijmakers CP.Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: radiotherapy target volume transformation and dose de-escalation.Radiother Oncol2018;128:472-8

[30] den Bosch S, Dijkema T, Verhoef LC, Zwijnenburg EM, Janssens GO, Kaanders JH. Patterns of recurrence in electively irradiated lymph node regions after definitive accelerated intensity modulated radiation therapy for head and neck squamous cell carcinoma.Int J Radiat Oncol Biol Phys2016;94:766-74

[31] van den Bosch S,Philippens MEP.Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of ¹⁸F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting.Radiother Oncol2019;130:39-45

[32] van den Bosch S,Kunze-Busch MC.Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.BMC Cancer2017;17:208 PMCID:PMC5361684

[33] Withers H,Taylor JM.Dose-response relationship for radiation therapy of subclinical disease.Int J Radiat Oncol Biol Phys1995;31:353-9

[34] Kaanders JHAM,Dijkema T,Raaijmakers CPJ.Advances in cancer imaging require renewed radiotherapy dose and target volume concepts.Radiother Oncol2020;148:140-2

[35] Deschuymer S,Duprez F.Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome.Radiother Oncol2020;143:24-9

[36] Sher DJ,Shah JL.Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer.Int J Radiat Oncol Biol Phys2021;109:932-40

[37] Deschuymer S,Duprez F.Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma: results on the quality of life.Qual Life Res2021;30:117-27

[38] Nevens D,Daisne JF.Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control.Radiother Oncol2017;122:171-7

[39] Maguire PD,Hardy SM.Single-arm phase 2 trial of elective nodal dose reduction for patients with locoregionally advanced squamous cell carcinoma of the head and neck.Int J Radiat Oncol Biol Phys2018;100:1210-6 PMCID:PMC6062207

[40] Tsai CJ,Riaz N.Reducing the radiation therapy dose prescription for elective treatment areas in human papillomavirus-associated oropharyngeal carcinoma being treated with primary chemoradiotherapy at memorial sloan kettering cancer center.Pract Radiat Oncol2019;9:98-101

[41] Driessen DAJJ,Weijs WLJ.Novel diagnostic approaches for assessment of the clinically negative neck in head and neck cancer patients.Front Oncol2020;10:637513 PMCID:PMC7901951

[42] Chow LQM.Head and neck cancer.N Engl J Med2020;382:60-72

[43] Pollom EL,Durkee BY.Prognostic value of midtreatment FDG-PET in oropharyngeal cancer.Head Neck2016;38:1472-8

[44] Garibaldi C,Cremonesi M.Interim ¹⁸F-FDG PET/CT during chemoradiation therapy in the management of head and neck cancer patients: a systematic review.Int J Radiat Oncol Biol Phys2017;98:555-73

[45] Martens RM,Ali M.Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review.Oral Oncol2019;88:75-83

[46] Bonomo P,Olmetto E.What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy?.Eur J Nucl Med Mol Imaging2018;45:2122-38 PMCID:PMC6182396

[47] Hentschel M,Schreiber A.Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.Eur J Nucl Med Mol Imaging2011;38:1203-11

[48] Kim S,Kim JS.Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients.Radiat Oncol J2018;36:95-102 PMCID:PMC6074065

[49] Lin P,Lee M.Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.Eur J Nucl Med Mol Imaging2017;44:801-11

[50] Min M,Lee MT.Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma.Eur J Nucl Med Mol Imaging2015;42:1984-94 PMCID:PMC4623084

[51] Chen SW,Yen KY.Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.Laryngoscope2014;124:2732-8

[52] Min M,Lee M.Prognostic value of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography scan carried out during and after radiation therapy for head and neck cancer using visual therapy response interpretation criteria.Clin Oncol (R Coll Radiol)2016;28:393-401

[53] Morgan HE.Adaptive radiotherapy for head and neck cancer.Cancers Head Neck2020;5:1 PMCID:PMC6953291

[54] Geets X,Lee JA.Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy.Radiother Oncol2007;85:105-15

[55] Castelli J,Louvel G.Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia.Radiat Oncol2015;10:6 PMCID:PMC4311461

[56] Vorwerk H,Schiller R.Protection of quality and innovation in radiation oncology: the prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources during radiotherapy with IMRT.Strahlenther Onkol2014;190:433-43

[57] Chen L,Shen C,Wang J.Synthetic CT generation from CBCT images via deep learning.Med Phys2020;47:1115-25 PMCID:PMC7067667

[58] van Dijk LV,Aljabar P.Improving automatic delineation for head and neck organs at risk by Deep Learning Contouring.Radiother Oncol2020;142:115-23

[59] Madani I,Boterberg T.Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer.Radiother Oncol2011;101:351-5

[60] Berwouts D,Duprez F.Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial.Radiother Oncol2013;107:310-6

[61] Gouw ZAR,Vogel WV,Sonke JJ.Single-center prospective trial investigating the feasibility of serial FDG-PET guided adaptive radiation therapy for head and neck cancer.Int J Radiat Oncol Biol Phys2020;108:960-8

[62] Berwouts D,Duprez F.Long-term outcome of ¹⁸F-fluorodeoxyglucose-positron emission tomography-guided dose painting for head and neck cancer: Matched case-control study.Head Neck2017;39:2264-75

[63] Fleury B,Barnoud R.Microscopic extensions of head and neck squamous cell carcinomas: impact for clinical target volume definition.Cancer Radiother2014;18:666-71

[64] Ligtenberg H,Caldas-Magalhaes J.Modality-specific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI.Radiother Oncol2017;123:63-70

[65] Grégoire V,Le QT.Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.Radiother Oncol2018;126:3-24

[66] Bristow RG,Baumann M.Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.Lancet Oncol2018;19:e240-51

[67] Lee N,Beattie B.Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma.Int J Radiat Oncol Biol Phys2016;96:9-17 PMCID:PMC5035649

[68] Troost EG,Hoffmann AL,Oyen WJ.18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.J Nucl Med2010;51:866-74

[69] Hoeben BA,Span PN.18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.J Nucl Med2013;54:532-40